NCT01735968 - A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 27, 2013

Primary Completion Date

October 19, 2018

Study Completion Date

October 19, 2018

Conditions

3rd Line GIST

Interventions

DRUG

ST571 + BYL719

Evaluable patients must meet the minimum treatment and safety evaluation requirements of the study. Patients will be treated until they experience progression of disease, withdraw consent, or experience unacceptable toxicity. One study cycle equals 28 days.

Trial Locations (11)

3000

Novartis Investigative Site, Leuven

10060

Novartis Investigative Site, Candiolo

13125

Novartis Investigative Site, Berlin

33076

Novartis Investigative Site, Bordeaux

40138

Novartis Investigative Site, Bologna

45147

Novartis Investigative Site, Essen

97239

Oregon Health and Science University Dept. of OHSU (3), Portland

9713 GZ

Novartis Investigative Site, Groningen

2300 RC

Novartis Investigative Site, Leiden

08035

Novartis Investigative Site, Barcelona

LS9 7TF

Novartis Investigative Site, Leeds